[go: up one dir, main page]

LT2582683T - Podagros ir hiperuricemijos gydymas - Google Patents

Podagros ir hiperuricemijos gydymas

Info

Publication number
LT2582683T
LT2582683T LTEP11796324.9T LT11796324T LT2582683T LT 2582683 T LT2582683 T LT 2582683T LT 11796324 T LT11796324 T LT 11796324T LT 2582683 T LT2582683 T LT 2582683T
Authority
LT
Lithuania
Prior art keywords
hyperuricemia
gout
treatment
Prior art date
Application number
LTEP11796324.9T
Other languages
English (en)
Inventor
Jeffrey Miner
Barry Quart
Jean-Luc Girardet
Original Assignee
Ardea Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45348529&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2582683(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ardea Biosciences, Inc. filed Critical Ardea Biosciences, Inc.
Publication of LT2582683T publication Critical patent/LT2582683T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEP11796324.9T 2010-06-15 2011-06-14 Podagros ir hiperuricemijos gydymas LT2582683T (lt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US35500410P 2010-06-15 2010-06-15
US41144910P 2010-11-08 2010-11-08
US201161430522P 2011-01-06 2011-01-06
US201161489420P 2011-05-24 2011-05-24
PCT/US2011/040398 WO2011159732A1 (en) 2010-06-15 2011-06-14 Treatment of gout and hyperuricemia

Publications (1)

Publication Number Publication Date
LT2582683T true LT2582683T (lt) 2018-06-11

Family

ID=45348529

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP11796324.9T LT2582683T (lt) 2010-06-15 2011-06-14 Podagros ir hiperuricemijos gydymas

Country Status (19)

Country Link
US (3) US9216179B2 (lt)
EP (1) EP2582683B1 (lt)
JP (1) JP5964821B2 (lt)
CA (1) CA2802407C (lt)
CY (1) CY1120473T1 (lt)
DK (1) DK2582683T3 (lt)
ES (1) ES2670700T3 (lt)
HR (1) HRP20180780T1 (lt)
HU (1) HUE038265T2 (lt)
LT (1) LT2582683T (lt)
NO (1) NO2019008I1 (lt)
PL (1) PL2582683T3 (lt)
PT (1) PT2582683T (lt)
RS (1) RS57275B1 (lt)
SI (1) SI2582683T1 (lt)
SM (1) SMT201800266T1 (lt)
TR (1) TR201806828T4 (lt)
WO (1) WO2011159732A1 (lt)
ZA (1) ZA201300055B (lt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011126852A2 (en) 2010-03-30 2011-10-13 Ardea Biosciences, Inc. Treatment of gout
LT2582683T (lt) * 2010-06-15 2018-06-11 Ardea Biosciences, Inc. Podagros ir hiperuricemijos gydymas
JP6025853B2 (ja) * 2011-11-03 2016-11-16 アルデア バイオサイエンシーズ インク． ３，４−二置換ピリジン化合物、その使用方法、および、該化合物を含む組成物
AR091651A1 (es) 2012-07-03 2015-02-18 Ardea Biosciences Inc Elaboracion de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico
US8883857B2 (en) 2012-12-07 2014-11-11 Baylor College Of Medicine Small molecule xanthine oxidase inhibitors and methods of use
CN103613552A (zh) * 2013-12-02 2014-03-05 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸钠的新晶型及其制备方法
CN103755651A (zh) * 2013-12-23 2014-04-30 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸的盐的新晶型及其制备方法
WO2015095703A1 (en) 2013-12-20 2015-06-25 Crystal Pharmatech, Inc. Novel salts and co-crystals of lesinurad
JP2015160847A (ja) * 2014-02-28 2015-09-07 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ 小分子のキサンチンオキシダーゼ阻害剤および使用方法
CN105622531A (zh) 2015-04-03 2016-06-01 南京明德新药研发股份有限公司 轴手性异构体及其制备方法和制药用途
WO2016203436A1 (en) * 2015-06-19 2016-12-22 Dr. Reddy's Laboratories Limited Amorphous and amorphous solid dispersion of lesinurad and their preparation
EP3112334A1 (en) 2015-06-29 2017-01-04 DPx Fine Chemicals Austria GmbH & CoKG Process for manufacturing 1-cyclopropyl-naphthalenes
JP6976946B2 (ja) * 2015-12-08 2021-12-08 アーディア・バイオサイエンシーズ・インコーポレイテッドArdea Biosciences, Inc. 生理活性の強い、ｕｒａｔ１のインヒビターを含む医薬組成物
US11447916B2 (en) 2018-10-26 2022-09-20 The Procter & Gamble Company Paper towel rolls
CA3060211C (en) 2018-10-26 2025-05-13 The Procter & Gamble Company TOILET PAPER ROLLS
US11633076B2 (en) 2018-10-26 2023-04-25 The Procter & Gamble Company Sanitary tissue product rolls
US11700979B2 (en) 2018-10-26 2023-07-18 The Procter & Gamble Company Sanitary tissue product rolls
EP4019048A4 (en) * 2019-08-21 2023-10-04 The University of Tokyo ABCC11 INHIBITOR
CN110824067B (zh) * 2019-12-11 2024-12-27 天津药物研究院有限公司 一种非布司他中基因毒性杂质的检测方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2377937T3 (es) 2003-12-26 2012-04-03 Kissei Pharmaceutical Co., Ltd. Derivados de benzimidazol y usos médicos de los mismos
US20060189811A1 (en) 2004-07-23 2006-08-24 Fujiyakuhin Co., Ltd. Process for producing 1,2,4-triazole compound and intermediate therefor
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
CN101083987B (zh) 2004-08-25 2011-01-26 阿迪亚生命科学公司 作为HIV逆转录酶抑制剂的S-三唑基α-巯基乙酰苯胺
US20090042887A1 (en) 2007-01-19 2009-02-12 Tap Pharmaceutical Products, Inc. Methods for Preventing or Reducing the Number of Gout Flares Using Xanthine Oxidoreductase Inhibitors and Anti-Inflammatory Agents
JP5099794B2 (ja) * 2007-11-27 2012-12-19 アルデア バイオサイエンシーズ インク． 新規化合物、組成物、及び使用方法
EP2328879A4 (en) 2008-09-04 2012-05-09 Ardea Biosciences Inc CORRESPONDING COMPOUNDS, COMPOSITIONS, AND METHODS OF USE FOR MODULATING URIC ACID RATES
US8242154B2 (en) 2008-09-04 2012-08-14 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US8173690B2 (en) 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US20100160351A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
EP2432774A4 (en) * 2009-05-20 2013-01-02 Ardea Biosciences Inc COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING URIC ACID RATES
EP2266966A1 (en) 2009-06-11 2010-12-29 Chemo Ibérica, S.A. A process for the preparation of febuxostat
US8524754B2 (en) * 2010-01-08 2013-09-03 Ardea Biosciences, Inc. Polymorphic, crystalline and mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio) acetate, and uses thereof
WO2011126852A2 (en) 2010-03-30 2011-10-13 Ardea Biosciences, Inc. Treatment of gout
LT2582683T (lt) * 2010-06-15 2018-06-11 Ardea Biosciences, Inc. Podagros ir hiperuricemijos gydymas
CA2803446C (en) * 2010-07-02 2019-06-04 University Health Network Use of plk4 antagonists for treating pten mutant diseases
EP2627331A4 (en) 2010-10-15 2014-03-12 Ardea Biosciences Inc METHODS OF TREATING HYPERURICEMIA AND RELATED DISEASES
SG190902A1 (en) 2010-12-30 2013-07-31 Ardea Biosciences Inc Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio) acetic acid and uses thereof
WO2012162323A1 (en) 2011-05-24 2012-11-29 Ardea Biosciences, Inc. Hypertension and hyperuricemia

Also Published As

Publication number Publication date
SI2582683T1 (en) 2018-07-31
HUE038265T2 (hu) 2018-10-29
US9216179B2 (en) 2015-12-22
US20160143889A1 (en) 2016-05-26
US20190015392A1 (en) 2019-01-17
ZA201300055B (en) 2018-05-30
US20130178484A1 (en) 2013-07-11
DK2582683T3 (en) 2018-06-06
JP2013528650A (ja) 2013-07-11
PL2582683T3 (pl) 2018-08-31
WO2011159732A1 (en) 2011-12-22
NO2019008I1 (no) 2019-02-19
ES2670700T3 (es) 2018-05-31
RS57275B1 (sr) 2018-08-31
EP2582683A4 (en) 2014-04-30
CA2802407A1 (en) 2011-12-22
PT2582683T (pt) 2018-05-25
JP5964821B2 (ja) 2016-08-03
TR201806828T4 (tr) 2018-06-21
CY1120473T1 (el) 2019-07-10
EP2582683A1 (en) 2013-04-24
EP2582683B1 (en) 2018-03-21
SMT201800266T1 (it) 2018-07-17
HRP20180780T1 (hr) 2018-07-13
CA2802407C (en) 2018-01-23

Similar Documents

Publication Publication Date Title
ZA201300055B (en) Treatment of gout and hyperuricemia
IL248530A0 (en) Biomarkers and treatment methods
ZA201304280B (en) Treatment of jak2-mediated conditions
GB2498121B (en) Treatment device and method of use
ZA201207973B (en) Treatment of gout
IL222227A0 (en) Pyrazol - 4 - heterocyclyl-carboxamide compounds and methods of use
EP2464227A4 (en) COMPOUNDS AND METHODS OF USE
EP2627331A4 (en) METHODS OF TREATING HYPERURICEMIA AND RELATED DISEASES
GB0915515D0 (en) Treatment of vasculoproliferative conditions
EP2574172A4 (en) MATERIALS AND METHOD FOR TREATING INFLAMMATION
IL265950A (en) Detection and treatment of leprosy
AP3480A (en) Phosphaplatins and their use for treatment of cancers
ZA201301936B (en) Methods and compositions for treatment of diabetes and dyslipidemia
IL256026B (en) Treatment methods
PL2575858T3 (pl) Sposoby leczenia zespołu nerczycowego
GB0908101D0 (en) Treatment of stress
ZA201207496B (en) Treatment of chicory
ZA201404738B (en) Treatment of type i and type ii diabetes
ZA201207497B (en) Treatment of chicory
EP2585103A4 (en) METHOD OF TREATMENT
ZA201301175B (en) Biomarkers and methods of treatment
GB0919985D0 (en) Treatment of grain
GB201014736D0 (en) Treatment of hepatitis C
GB201003917D0 (en) Method of treatment